person · Reporting owner

Lucchese Cynthia L

Disclosed activity across 5 companies

Tapewire entity: 48323
SEC CIK: 0001337319

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COOPER COMPANIES, INC.COO · Entity 3395	Director	April 01, 2026	April 06, 2026
Intersect ENT, Inc.XENT · Entity 127294	Director	May 13, 2022	May 16, 2022
Mobia Medical, Inc.MOBI · Entity 5669	Director	May 07, 2026	May 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COOPER COMPANIES, INC.

Report date April 01, 2026 · Filed April 06, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	12,767	Reported balance After 2026-04-01 transaction · row 1 1 source row Row 1 · 2026-04-01 · Exercise / conversion · Acquired 3,322 · Balance 12,767
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	0	Reported balance After 2026-04-01 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-04-01 · Exercise / conversion · Disposed 3,322 · Balance 0 F1: This award has no expiration date. Units will either vest or be forfeited.
Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	3,779	Reported balance After 2026-04-01 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-04-01 · Grant · Acquired 3,779 · Balance 3,779 F1: This award has no expiration date. Units will either vest or be forfeited.

Filing footnotes · ownership attribution and instrument terms

F1: This award has no expiration date. Units will either vest or be forfeited.

Intersect ENT, Inc.

Report date May 13, 2022 · Filed May 16, 2022

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Ending reported balance After 2022-05-13 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2022-05-13 · Other · Disposed 16,383 · Balance 3,239 F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Row 2 · 2022-05-13 · Other · Disposed 3,239 · Balance 0 F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2029-01-15	Direct	Reported balance After 2022-05-13 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2022-05-13 · Other · Disposed 3,220 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.02 · Expires 2029-06-03	Direct	Reported balance After 2022-05-13 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2022-05-13 · Other · Disposed 5,172 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.00 · Expires 2031-03-15	Direct	Reported balance After 2022-05-13 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2022-05-13 · Other · Disposed 3,390 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.50 · Expires 2031-06-02	Direct	Reported balance After 2022-05-13 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2022-05-13 · Other · Disposed 5,734 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.79 · Expires 2026-06-01	Direct	Reported balance After 2022-05-13 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.84 · Expires 2030-06-03	Direct	Reported balance After 2022-05-13 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2022-05-13 · Other · Disposed 9,666 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.12 · Expires 2024-07-08	Direct	Reported balance After 2022-05-13 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2022-05-13 · Other · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.05 · Expires 2028-06-04	Direct	Reported balance After 2022-05-13 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2022-05-13 · Other · Disposed 3,473 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.95 · Expires 2028-01-16	Direct	Reported balance After 2022-05-13 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2022-05-13 · Other · Disposed 2,797 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.45 · Expires 2025-06-03	Direct	Reported balance After 2022-05-13 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2022-05-13 · Other · Disposed 12,500 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.05 · Expires 2027-05-31	Direct	Reported balance After 2022-05-13 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2022-05-13 · Other · Disposed 6,035 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.
Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.05 · Expires 2027-01-17	Direct	Reported balance After 2022-05-13 transaction · row 14 Instrument identity requires review; Table II rows are not merged. 1 source row Row 14 · 2022-05-13 · Other · Disposed 7,570 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes].

F2: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes.

Mobia Medical, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	125,000	Reported balance After 2026-05-11 transaction · row 1 1 source row Row 1 · 2026-05-11 · Purchase · Acquired 125,000 · Balance 125,000
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2036-05-07	Direct	31,520	Reported balance After 2026-05-07 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-07 · Grant · Acquired 31,520 · Balance 31,520 F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

HANGER, INC.

Report date October 03, 2022 · Filed October 04, 2022

Section 16 reporting ended · disclosed 2022-10-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-10-03 transaction · row 1 1 source row Row 1 · 2022-10-03 · Disposition to issuer · Disposed 67,851 · Balance 0 F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash.

Inari Medical, Inc.

Report date February 19, 2025 · Filed February 20, 2025

Section 16 reporting ended · disclosed 2025-02-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-02-19 transaction · row 1 1 source row Row 1 · 2025-02-19 · Other · Disposed 38,429 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.73	Direct	0	Reported balance After 2025-02-19 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-02-19 · Disposition to issuer · Disposed 49,719 · Balance 0 F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest.

F2: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration.

F3: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 11, 2026 Filed May 12, 2026 01:36 UTC	Mobia Medical, Inc. MOBI · Entity 5669	PurchaseCommon Stock	125,000	$15.00	$1,875,000.00	Disclosure SEC source: 0001628280-26-033810 · wk-form4_1778549807.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Read SEC document
May 07, 2026 Filed May 12, 2026 01:36 UTC	Mobia Medical, Inc. MOBI · Entity 5669	GrantStock Option · Derivative	31,520	$0.00 Strike: $15.00	$0.00	Disclosure SEC source: 0001628280-26-033810 · wk-form4_1778549807.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,520 Underlying: Common Stock · 31,520 shares Expires 2036-05-07 F1 · derivative.exercise_date: The stock option will vest in three substantially equal installments on the first three anniversaries of the grant date. Read SEC document
April 01, 2026 Filed Apr 6, 2026 21:14 UTC	COOPER COMPANIES, INC. COO · Entity 3395	GrantRestricted Stock Units · Derivative	3,779	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001337319-26-000001 · primarydocument.xml · derivative · entry 3 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,779 Underlying: Common Stock · 3,779 shares Expires not disclosed F1 · derivative.expiration_date: This award has no expiration date. Units will either vest or be forfeited. Read SEC document
April 01, 2026 Filed Apr 6, 2026 21:14 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionRestricted Stock Units · Derivative	3,322	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001337319-26-000001 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,322 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: This award has no expiration date. Units will either vest or be forfeited. Read SEC document
April 01, 2026 Filed Apr 6, 2026 21:14 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionCommon Stock	3,322	$0.00	$0.00	Disclosure SEC source: 0001337319-26-000001 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,767 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
December 22, 2025 Filed Dec 23, 2025 21:08 UTC	COOPER COMPANIES, INC. COO · Entity 3395	PurchaseCommon Stock	1,784	$84.06	$149,963.04	Disclosure SEC source: 0001337319-25-000002 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,445 Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:07 UTC	COOPER COMPANIES, INC. COO · Entity 3395	GrantRestricted Stock Units · Derivative	3,322	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-25-002970 · primarydocument.xml · derivative · entry 3 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,322 Underlying: Common Stock · 3,322 shares Expires not disclosed F1 · derivative.expiration_date: This award has no expiration date. Units will either vest or be forfeited. Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:07 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionRestricted Stock Units · Derivative	2,721	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-25-002970 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,721 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.expiration_date: This award has no expiration date. Units will either vest or be forfeited. Read SEC document
April 01, 2025 Filed Apr 3, 2025 20:07 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionCommon Stock	2,721	$0.00	$0.00	Disclosure SEC source: 0001562180-25-002970 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 19, 2025 Filed Feb 20, 2025 01:04 UTC	Inari Medical, Inc. NARI · Entity 83035	Disposition to issuerStock Option · Derivative	49,719	Not disclosed Strike: $5.73	Not disclosed	Disclosure SEC source: 0001127602-25-005737 · form4.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,719 shares Expires not disclosed F3 · price: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.exercise_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. F3 · derivative.expiration_date: At the Effective Time, each outstanding option, whether vested or unvested, was cancelled and converted into the right to receive an amount of cash equal to the product of (i) the aggregate number of shares of Common Stock underlying such option immediately prior to the Effective Time, multiplied by (ii) the amount, if any, by which the Merger Consideration exceeds the exercise price per share of such option, subject to any applicable withholding taxes and in accordance with the terms of the Merger Agreement. Read SEC document
February 19, 2025 Filed Feb 20, 2025 01:04 UTC	Inari Medical, Inc. NARI · Entity 83035	OtherCommon Stock	38,429	Not disclosed	Not disclosed	Disclosure SEC source: 0001127602-25-005737 · form4.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. F2 · shares: Includes 4,126 restricted stock units ("RSUs"). At the Effective Time, each outstanding award of RSUs was canceled and converted into the right to receive an amount in cash equal to the product of the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time, multiplied by the Merger Consideration. F1 · price: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated January 6, 2025, by and among Stryker Corporation ("Parent"), Eagle 1 Merger Sub, Inc. ("Merger Sub"), and Inari Medical, Inc. ("Issuer") on February 19, 2025 (the "Effective Time"), Merger Sub merged with and into Issuer, with Issuer surviving as a wholly owned subsidiary of Parent upon consummation of the transactions contemplated by the Merger Agreement. At the Effective Time, each outstanding share of common stock of the Issuer ("Common Stock") was cancelled and converted into the right to receive $80.00 in cash (the "Merger Consideration"), without interest. Read SEC document
April 24, 2024 Filed Apr 26, 2024 20:49 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	4,126	$42.41	$174,983.66	Disclosure SEC source: 0001127602-24-013469 · form4.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,429 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document
April 24, 2024 Filed May 31, 2024 20:44 UTC Amendment	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	4,126	$42.41	$174,983.66	Disclosure SEC source: 0001127602-24-017125 · form4a.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,429 F1 · shares: Represents restricted stock units granted on April 24, 2024 to the Reporting Person that vest in full on the earlier of (1) the day prior to the Issuer's next annual meeting of stockholders or (2) one year from the date of grant. Read SEC document
April 01, 2024 Filed Apr 3, 2024 21:53 UTC	COOPER COMPANIES, INC. COO · Entity 3395	GrantRestricted Stock Units · Derivative	2,721	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-24-003263 · primarydocument.xml · derivative · entry 3 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,721 Underlying: Common Stock · 2,721 shares Expires not disclosed F2 · derivative.expiration_date: RSU Expiration Date: This award has no expiration date. Units will either vest or be forfeit. Read SEC document
April 01, 2024 Filed Apr 3, 2024 21:53 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionRestricted Stock Units · Derivative	2,892	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-24-003263 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,892 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Adjusted to reflect Issuer's 4-for-1 stock split effected on February. 16, 2024. F2 · derivative.expiration_date: RSU Expiration Date: This award has no expiration date. Units will either vest or be forfeit. F1 · derivative.underlying_shares: Adjusted to reflect Issuer's 4-for-1 stock split effected on February. 16, 2024. Read SEC document
April 01, 2024 Filed Apr 3, 2024 21:53 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionCommon Stock	2,892	$0.00	$0.00	Disclosure SEC source: 0001562180-24-003263 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,940 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Adjusted to reflect Issuer's 4-for-1 stock split effected on February. 16, 2024. F1 · balance_after: Adjusted to reflect Issuer's 4-for-1 stock split effected on February. 16, 2024. Read SEC document
May 18, 2023 Filed May 19, 2023 22:16 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	2,412	$0.00	$0.00	Disclosure SEC source: 0001127602-23-016362 · form4.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,303 F1 · shares: Represents RSUs granted on May 18, 2023, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2024 annual meeting. Read SEC document
April 01, 2023 Filed Apr 3, 2023 22:25 UTC	COOPER COMPANIES, INC. COO · Entity 3395	GrantRestricted Stock Units · Derivative	723	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-23-003269 · primarydocument.xml · derivative · entry 3 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 723 Underlying: Common Stock · 723 shares Expires not disclosed F1 · derivative.exercise_price: RSU Exercise Price: There is no exercise price associated with the grant of Restricted Stock Units. F2 · derivative.expiration_date: RSU Expiration Date: This award has no expiration date. Units will either vest or be forfeit. Read SEC document
April 01, 2023 Filed Apr 3, 2023 22:25 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionRestricted Stock Units · Derivative	512	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-23-003269 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 512 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: RSU Exercise Price: There is no exercise price associated with the grant of Restricted Stock Units. F2 · derivative.expiration_date: RSU Expiration Date: This award has no expiration date. Units will either vest or be forfeit. Read SEC document
April 01, 2023 Filed Apr 3, 2023 22:25 UTC	COOPER COMPANIES, INC. COO · Entity 3395	Exercise / conversionCommon Stock	512	$0.00	$0.00	Disclosure SEC source: 0001562180-23-003269 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 03, 2022 Filed Oct 4, 2022 17:19 UTC	HANGER, INC. HNGR · Entity 14115	Disposition to issuerCommon Stock	67,851	$18.75	$1,272,206.25	Disclosure SEC source: 0001567619-22-018189 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Represents shares of issuer's common stock and restricted stock units relating to such common stock that were disposed of in connection with the merger of Hero Merger Sub, Inc. with and into issuer (the "Merger") pursuant to the Agreement and Plan of Merger, dated as of July 21, 2022, by and among issuer, Hero Parent, Inc. and Hero Merger Sub, Inc. (the "Merger Agreement"). At the effective time of the Merger, each issued and outstanding share of issuer's common stock (subject to certain exceptions described in the Merger Agreement) and each restricted stock unit were canceled and converted into the right to receive $18.75 in cash. Read SEC document
October 01, 2022 Filed Oct 4, 2022 20:09 UTC	COOPER COMPANIES, INC. COO · Entity 3395	GrantRestricted Stock Units · Derivative	512	$0.00 Strike: $0.00	$0.00	Disclosure SEC source: 0001562180-22-006996 · primarydocument.xml · derivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 512 Underlying: Common Stock · 512 shares Expires not disclosed F1 · derivative.exercise_price: RSU Exercise Price: There is no exercise price associated with the grant of Restricted Stock Units. F2 · derivative.expiration_date: RSU Expiration Date: This award has no expiration date. Units will either vest or be forfeit. Read SEC document
June 02, 2022 Filed Jun 3, 2022 16:48 UTC	HANGER, INC. HNGR · Entity 14115	GrantCommon Stock	9,911	$0.00	$0.00	Disclosure SEC source: 0001567619-22-012304 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,851 F1 · shares: Consists of shares of restricted stock granted under the Company's 2022 Omnibus Incentive Plan (the "Plan"), which vest 100% on June 2, 2023, subject to certain provisions of the Plan. Read SEC document
May 26, 2022 Filed May 27, 2022 20:38 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	2,420	$0.00	$0.00	Disclosure SEC source: 0001127602-22-015879 · form4.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,891 F1 · shares: Represents RSUs granted on May 26, 2022, to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2023 annual meeting. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	7,570	$28.25 Strike: $13.05	$213,852.50	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 14 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,570 shares Expires 2027-01-17 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	6,035	$28.25 Strike: $26.05	$170,488.75	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 13 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,035 shares Expires 2027-05-31 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	12,500	$28.25 Strike: $27.45	$353,125.00	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 12 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2025-06-03 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	2,797	$28.25 Strike: $33.95	$79,015.25	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 11 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,797 shares Expires 2028-01-16 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Options (Right to buy) · Derivative	3,473	$28.25 Strike: $42.05	$98,112.25	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 10 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,473 shares Expires 2028-06-04 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	25,000	$28.25 Strike: $11.12	$706,250.00	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 9 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2024-07-08 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	9,666	$28.25 Strike: $11.84	$273,064.50	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 8 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,666 shares Expires 2030-06-03 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	12,500	$28.25 Strike: $13.79	$353,125.00	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 7 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2026-06-01 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	5,734	$28.25 Strike: $16.50	$161,985.50	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 6 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,734 shares Expires 2031-06-02 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	3,390	$28.25 Strike: $21.00	$95,767.50	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 5 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,390 shares Expires 2031-03-15 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	5,172	$28.25 Strike: $23.02	$146,109.00	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 4 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,172 shares Expires 2029-06-03 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherStock Option (right to buy) · Derivative	3,220	$28.25 Strike: $28.58	$90,965.00	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · derivative · entry 3 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,220 shares Expires 2029-01-15 F3 · kind: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each option granted by the Issuer to purchase Issuer Common Stock other than options subject to performance-based vesting conditions (each, an 'Issuer Option') that was outstanding and unexercised as of immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer Option and (2) the excess, if any, of the Common Stock Merger Consideration over the exercise price of such Issuer Option, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherCommon Stock	3,239	$28.25	$91,501.75	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · nonDerivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. F2 · price: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was subject to vesting conditions based solely on continued employment with or service to the Company or any of its subsidiaries (each, an 'Issuer RSU') that was outstanding and unvested immediately prior to the Effective Time was cancelled and automatically converted into the right to receive an amount in cash equal to the product of (1) the aggregate number of Issuer Common Stock subject to such Issuer RSU and (2) the Common Stock Merger Consideration, subject to any required withholding of taxes. Read SEC document
May 13, 2022 Filed May 16, 2022 18:35 UTC	Intersect ENT, Inc. XENT · Entity 127294	OtherCommon Stock	16,383	$28.25	$462,819.75	Disclosure SEC source: 0001562180-22-004069 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,239 F1 · kind: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. F1 · price: Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger (the 'Merger Agreement'), dated August 6, 2021, by and among the Issuer, Medtronic, Inc. ('Parent') and Project Kraken Merger Sub, Inc., a wholly-owned subsidiary of Parent ('Merger Sub'), including the consummation of the merger (the 'Merger') between Issuer and Merger Sub on May 13, 2022. Pursuant to the Merger Agreement, as of the effective time of the Merger (the 'Effective Time'), [each outstanding share of Issuer common stock, $0.001 par value per share ('Issuer Common Stock'), was cancelled, retired and converted into the right to receive an amount equal to $28.25 in cash, without interest thereon (the 'Common Stock Merger Consideration'), subject to any required withholding of taxes]. Read SEC document
June 03, 2021 Filed Jun 7, 2021 21:11 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	5,734	$0.00 Strike: $16.50	$0.00	Disclosure SEC source: 0001562180-21-004113 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,734 Underlying: Common Stock · 5,734 shares Expires 2031-06-02 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 3, 2021. Read SEC document
June 03, 2021 Filed Jun 7, 2021 21:11 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	3,239	$0.00	$0.00	Disclosure SEC source: 0001562180-21-004113 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,622 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 3, 2022. F2 · balance_after: Includes 3,239 restricted stock units. Read SEC document
May 27, 2021 Filed May 28, 2021 22:37 UTC	Inari Medical, Inc. NARI · Entity 83035	GrantCommon Stock	1,380	$0.00	$0.00	Disclosure SEC source: 0001562180-21-003844 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,471 F1 · shares: Represents RSUs granted on May 27, 2021 to the Reporting Person that vest in full on the earlier to occur of (i) the one-year anniversary of the grant date and (ii) the date of the 2022 annual meeting. Read SEC document
May 26, 2021 Filed May 27, 2021 17:14 UTC	HANGER, INC. HNGR · Entity 14115	GrantCommon Stock	5,484	$0.00	$0.00	Disclosure SEC source: 0001567619-21-011282 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,940 F1 · shares: Consists of shares of restricted stock granted under the Company's 2019 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 26, 2022, subject to certain provisions of the Plan. Read SEC document
March 16, 2021 Filed Mar 18, 2021 19:32 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	3,390	$0.00 Strike: $21.00	$0.00	Disclosure SEC source: 0001562180-21-002359 · primarydocument.xml · derivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,390 Underlying: Common Stock · 3,390 shares Expires 2031-03-15 F1 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on January 1, 2021. Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:50 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	9,666	$0.00 Strike: $11.84	$0.00	Disclosure SEC source: 0001562180-20-004316 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,666 Underlying: Common Stock · 9,666 shares Expires 2030-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2020. Read SEC document
June 04, 2020 Filed Jun 8, 2020 16:50 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	5,011	$0.00	$0.00	Disclosure SEC source: 0001562180-20-004316 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,383 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2021. F2 · balance_after: Includes 5,011 restricted stock units. Read SEC document
May 27, 2020 Filed May 27, 2020 22:31 UTC	Inari Medical, Inc. NARI · Entity 83035	PurchaseCommon Stock	28,091	$19.00	$533,729.00	Disclosure SEC source: 0001209191-20-032406 · doc4.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,091 Read SEC document
May 20, 2020 Filed May 21, 2020 16:44 UTC	HANGER, INC. HNGR · Entity 14115	GrantCommon Stock	8,178	$0.00	$0.00	Disclosure SEC source: 0001567619-20-010922 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,456 F1 · shares: Consists of shares of restricted stock granted under the Company's 2019 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 20, 2021, subject to certain provisions of the Plan. Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:10 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantStock Option (right to buy) · Derivative	5,172	$0.00 Strike: $23.02	$0.00	Disclosure SEC source: 0001562180-19-003398 · primarydocument.xml · derivative · entry 2 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,172 Underlying: Common Stock · 5,172 shares Expires 2029-06-03 F3 · derivative.exercise_date: The shares subject to the option vest in 12 equal monthly installments commencing on June 4, 2019. Read SEC document
June 04, 2019 Filed Jun 6, 2019 18:10 UTC	Intersect ENT, Inc. XENT · Entity 127294	GrantCommon Stock	2,312	$0.00	$0.00	Disclosure SEC source: 0001562180-19-003398 · primarydocument.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,372 F1 · shares: Represents restricted stock units granted pursuant to the Intersect ENT, Inc. 2014 Equity Incentive Plan. Each restricted stock unit represents a right to receive one share of Intersect ENT, Inc. common stock upon vesting. The restricted stock units vest one year from grant date on June 4, 2020. F2 · balance_after: Includes 2,312 restricted stock units. Read SEC document
May 23, 2019 Filed May 24, 2019 17:54 UTC	HANGER, INC. HNGR · Entity 14115	GrantCommon Stock	6,969	$0.00	$0.00	Disclosure SEC source: 0001567619-19-012153 · doc1.xml · nonDerivative · entry 1 Lucchese Cynthia L · CIK 0001337319 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,278 F1 · shares: Consists of shares of restricted stock granted under the Company's 2019 Omnibus Incentive Plan (the "Plan"), which vest 100% on May 23, 2020, subject to certain provisions of the Plan. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.